Iron Chelation Therapy for Transfusional Iron Overload: A Swift Evolution

REFERENCES

• Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin. 2009;33(Suppl. 1):S46–S57.
   Google Scholar
• Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364(2):146–156.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, . Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574–578.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, . Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
   PubMed Web of Science ®Google Scholar
• Delea TE, Edelsberg J, Sofrygin O, . Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919–1929.
   PubMed Web of Science ®Google Scholar
• Musallam K, Cappellini MD, Taher A. Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood. Pediatrics. 2008;121(5):e1426–e1429.
   Web of Science ®Google Scholar
• Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26–36.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet. 1987;1(8545):1294–1295.
   PubMed Web of Science ®Google Scholar
• Piga A, Roggero S, Salussolia I, Massano D, Serra M, Longo F. Deferiprone. Ann NY Acad Sci. 2010;1202:75–78.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, . Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–3744.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002;360(9332):516–520.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, . Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733–3737.
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489–496.
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Capra M, . Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42(3):247–251.
   PubMed Web of Science ®Google Scholar
• Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103(2):361–364.
   PubMed Web of Science ®Google Scholar
• Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. Ann NY Acad Sci. 2010;1202:79–86.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, . A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Lai ME, Grady RW, Vacquer S, . Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis. 2010;45(2):136–139.
   PubMed Web of Science ®Google Scholar
• Telfer PT, Warburton F, Christou S, . Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009;94(12):1777–1778.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin. 2009;33(Suppl. 1):S58–S69.
   Google Scholar
• Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9(13):2391–2402.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, . A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455–3462.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, . Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood. 2009; DO1 10.1182/blood-2010-11–316646.
   Google Scholar
• Cappellini MD, Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol. 2009;122(2-3):165–173.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Onyekwere O, Porter J, . A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501–508.
   PubMed Web of Science ®Google Scholar
• Porter J, Galanello R, Saglio G, . Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168–176.
   PubMed Web of Science ®Google Scholar
• Taher A, El-Beshlawy A, Elalfy MS, . Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458–465.
   PubMed Web of Science ®Google Scholar
• Taher A, Cappellini MD, Vichinsky E, . Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147(5):752–759.
   PubMed Web of Science ®Google Scholar
• Porter JB, Piga A, Cohen A, . Safety of deferasirox (Exjade®) in patients with transfusion-dependent anemias and iron overload who achieve serum ferritin levels <1000 ng/ml during long-term treatment (Abstract 5423). Blood. 2008;112(11):5423.
   Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, . Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007;29(5):909–917.
   PubMed Web of Science ®Google Scholar
• Taher A, Al Jefri A, Elalfy MS, . Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from the ESCALATOR Trial. Acta Haematol. 2010;123(4):220–225.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter J, El-Beshlawy A, . Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–566.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, . Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364–2371.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, . Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48–54.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, . Continued improvement and normalization of myocardial T2* in patients with β-thalassemia major treated with deferasirox (Exjade®) for up to 3 years (Abstract 4276). Blood. 2010;116(21):4276.
   Web of Science ®Google Scholar
• Wood JC, Kang BP, Thompson A, . The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537–543.
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Capra M, . Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41–47.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT. Deferiprone or deferasirox for cardiac siderosis in β-thalassemia major. Haematologica. 2011;96(2):e5–e6; author reply: e7–e8.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD. Renal complications in transfusion-dependent β thalassaemia. Blood Rev. 2010;24(6):239–244.
   PubMed Web of Science ®Google Scholar
• Rienhoff HY Jr, Viprakasit V, Tay L, . A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica. 2011;96(4):521–525.
   PubMed Web of Science ®Google Scholar